Year: 2021

PRESS RELEASE RESS RELEASE Immunocore presents new data on tebentafusp in metastatic cutaneous melanoma (mCM) and uveal melanoma (mUM) at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting Tebentafusp in combination with checkpoint inhibitors had acceptable safety profile; preliminary evidence of clinical activity in anti-PD(L)1 relapsed/refractory mCM Survival benefit for tebentafusp monotherapy in mUM observed for both high and low gp100 protein tumor expression (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 9 November 2021) Immunocore Holdings Plc (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease,...

Figure 1Core photos of structural zones intersected during the Phase II summer drill program. A) Hematized fault zone in DR-21-025A along SE Warrior trend. B) Strongly clay-chlorite altered shear zone intersected in DR-21-025A. C) Strongly graphitic reactivated shear zone in DR-21-027 along the Bronco trend. D) Semi-brittle graphitic shear zone intersected in DR-21-027 peaking at 540 cps along the Bronco trend. E) Graphitic fault gouge zone in DR-21-030 along the Bronco trend. F) Intensely graphitic shear zone intersected along the Bronco trend in hole DR-21-031.Figure 2Plan map showing summer Phase II 2021 drill holes on the Davidson River Property.VANCOUVER, British Columbia, Nov. 09, 2021 (GLOBE NEWSWIRE) — Standard Uranium Ltd. (“Standard Uranium” or the “Company”) (TSX-V: STND) (OTCQB: STTDF)...

FREMONT, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) — Enphase Energy, Inc. (NASDAQ: ENPH), a global energy technology company and the world’s leading supplier of microinverter-based solar and battery systems, today announced that it will host its Investor Day in San Francisco, CA on November 16, 2021 at 9:00 a.m. PST. In-person attendance is by invitation only as space for the event is limited. The presentation will be a live virtual webcast found in the Events & Presentations section of Enphase Energy’s investor relations website at investor.enphase.com. A replay of the presentation will also be available in the Investor Relations section of the company’s website within 24 hours after the event concludes. About Enphase Energy, Inc. Enphase Energy, a global energy technology company based in Fremont, CA, is the world’s...

LEXINGTON, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) — Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Steven O’Day, Chief Medical Officer, and Dr. Dhan Chand, Scientific Director, Head of Drug Discovery at Agenus, will participate in a fireside chat hosted by B. Riley on Monday, November 15, 2021 at 12:00 PM EST. Dr. O’Day and Dr. Chand will discuss the AGEN1181 program (Fc-enhanced CTLA-4), following presentation of clinical data at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting on Friday, November 12th, 2021. Registration for the webinar can be done in advance at: https://www.webcaster4.com/Webcast/Page/2433/43588. A replay will be available...

3 of 5 (60%) patients achieved a partial response All 5 patients treated demonstrated tumor decrease from baselineBatiraxcept has been generally well-tolerated with no dose-limiting toxicitiesAravive to host conference call and webcast on November 12 at 8:30 a.m. ET to discuss updated data HOUSTON, Nov. 09, 2021 (GLOBE NEWSWIRE) — Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative, targeted therapeutics to treat life-threatening cancers, today announced that positive new data from the Phase 1b portion of its open-label Phase 1b/2 trial evaluating batiraxcept (AVB-500) in combination with cabozantinib in patients with clear cell renal cell carcinoma (ccRCC) will be presented at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting on November 13, 2021. The presentation will highlight...

MINNEAPOLIS, Nov. 09, 2021 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE) announced today its results for the third quarter ended September 30, 2021, which included the following highlights:Generated $1.9 million in total revenue, representing a decline of 3% compared to the prior-year period Generated $6.3 million in total revenue year-to-date through September 30, representing 16% growth compared to the prior-year period and a 52% increase above the comparable pre-pandemic period in 2019 Opened three new pediatric accounts in the third quarter, the largest quarterly addition in 2021 Announced R&D partnership with Koronis Biomedical Technologies Corporation (KBT) to design and develop a product for children under 20kg with limited kidney function, following a $1.7 million development grant from the National Institutes...

Total operating revenues of $106.6 million and Adjusted EBITDA of $74.5 million, up 12% and 30% YoY respectively Signed 1-year shipping time charter at approximately $100,000/day Secured up to $682m in new financing facilities, securing refinancing of the convertible bond on favorable terms and balance sheet liquidity improvement Growing customer interest for new FLNG projects Golar positioned to capitalize on macro tailwinds, benefiting from operating and financial leverage going into 2022+FLNG Hilli achieved another quarter of 100% commercial uptime. Capitalizing on record gas prices, Golar recently hedged half of its Q1 2022 Dutch Title Transfer Facility (“TTF”) exposure from the 0.2mtpa of additional 2022 production at a TTF price of $28/MMBtu, implying additional earnings to Golar for the quarter of $21.2 million (for each $1.00/MMBtu...